Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,809,273

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is a Beat in Store for Glaxo (GSK) This Earnings Season?

Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.

Sweta Killa headshot

Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review

AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.

Merck (MRK) to Report Q3 Earnings: Is a Beat in the Cards?

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.

Merck (MRK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC

Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, in the Biopharma segment are likely to have made up for lower sales in the Upjohn group in the third quarter.

Merck (MRK) Stock Moves -1.45%: What You Should Know

Merck (MRK) closed the most recent trading day at $78.67, moving -1.45% from the previous trading session.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

Bristol-Myers' (BMY) Opdivo Gets Positive CHMP View for ESCC

The CHMP passes a favorable opinion for the approval of Bristol-Myers' (BMY) Opdivo to address advanced/ metastatic esophageal squamous cell carcinoma in the EU.

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.

Eiger (EIGR) Up on Positive Results From Coronavirus Study

Eiger (EIGR) gains on positive results from the ILIAD study on peginterferon lambda-1a (lambda) in outpatients with mild-to-moderate COVID-19.

Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma

The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Q3 Earnings, Pause on Coronavirus Studies & Other Updates

J&J (JNJ) beats Q3 estimates for earnings and sales. J&J and Lilly (LLY) pause studies on their coronavirus vaccine and antibody candidates, respectively.

The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK

The Zacks Analyst Blog Highlights: JNJ, Eli Lilly, Merck, AbbVie and GSK

Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval

Regeneron (REGN) gets FDA nod for its triple antibody cocktail for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.

Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Celldex Initiates Early-Stage Antibody Study for Skin Disorder

Celldex (CLDX) is developing its monoclonal antibody candidate CDX-0159 as a potential treatment of chronic spontaneous urticaria.

Kinjel Shah headshot

Do J&J's Q3 Results Indicate a Sales Recovery for Big Pharma?

Investors typically look at J&J's (JNJ) results for signals regarding how the rest of the big drugmakers will fare.

Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed the most recent trading day at $80.71, moving +0.44% from the previous trading session.

Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev

Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.

J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2020 Guidance

J&J (JNJ) beats third-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.

Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC

Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.